Effectiveness and protection duration of Covid-19 vaccines and previous infection against any SARS-CoV-2 infection in young adults
Open Access
- 8 July 2022
- journal article
- research article
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-8
Abstract
Data on effectiveness and protection duration of Covid-19 vaccines and previous infection against general SARS-CoV-2 infection in general populations are limited. Here we evaluate protection from Covid-19 vaccination (primary series) and previous infection in 21,261 university students undergoing repeated surveillance testing between 8/8/2021–12/04/2021, during which B.1.617 (delta) was the dominant SARS-CoV-2 variant. Estimated mRNA-1273, BNT162b2, and AD26.COV2.S effectiveness against any SARS-CoV-2 infection is 75.4% (95% CI: 70.5-79.5), 65.7% (95% CI: 61.1-69.8), and 42.8% (95% CI: 26.1–55.8), respectively. Among previously infected individuals, protection is 72.9% when unvaccinated (95% CI: 66.1–78.4) and increased by 22.1% with full vaccination (95% CI: 15.8–28.7). Statistically significant decline in protection is observed for mRNA-1273 (P < .001), BNT162b2 (P < .001), but not Ad26.CoV2.S (P = 0.40) or previous infection (P = 0.12). mRNA vaccine protection dropped 29.7% (95% CI: 17.9–41.6) six months post- vaccination, from 83.2% to 53.5%. We conclude that the 2-dose mRNA vaccine series initially offers strong protection against general SARS-CoV-2 infection caused by the delta variant in young adults, but protection substantially decreases over time. These findings indicate that vaccinated individuals may still contribute to community spread. While previous SARS-CoV-2 infection consistently provides moderately strong protection against repeat infection from delta, vaccination yields a substantial increase in protection.Keywords
Funding Information
- Clemson University (1502934, 1502934, 1502934)
- U.S. Department of Health & Human Services | National Institutes of Health (P20 GM121342, P20 GM121342)
- U.S. Department of Health & Human Services | National Institutes of Health
This publication has 50 references indexed in Scilit:
- SalivaDirect: A simplified and flexible platform to enhance SARS-CoV-2 testing capacityMed, 2021
- Quantifying asymptomatic infection and transmission of COVID-19 in New York City using observed cases, serology, and testing capacityProceedings of the National Academy of Sciences, 2021
- Immunological memory to SARS-CoV-2 assessed for up to 8 months after infectionScience, 2021
- Efficacy and Safety of the mRNA-1273 SARS-CoV-2 VaccineNew England Journal of Medicine, 2021
- SARS-CoV-2 Transmission From People Without COVID-19 SymptomsJAMA Network Open, 2021
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 VaccineNew England Journal of Medicine, 2020
- Modelling the impact of presemester testing on COVID-19 outbreaks in university campusesBMJ Open, 2020
- Asymptomatic Transmission, the Achilles’ Heel of Current Strategies to Control Covid-19New England Journal of Medicine, 2020
- Temporal dynamics in viral shedding and transmissibility of COVID-19Nature Medicine, 2020
- A Solution to the Problem of Monotone Likelihood in Cox RegressionBiometrics, 2001